Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity.

Kurmi K, Hitosugi S, Wiese EK, Boakye-Agyeman F, Gonsalves WI, Lou Z, Karnitz LM, Goetz MP, Hitosugi T.

Cell Rep. 2018 Feb 6;22(6):1365-1373. doi: 10.1016/j.celrep.2018.01.030.

2.

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:108-116. doi: 10.1016/j.leukres.2017.09.005. Epub 2017 Sep 20.

PMID:
28957699
3.

Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.

Baehr CA, Huntoon CJ, Hoang SM, Jerde CR, Karnitz LM.

J Biol Chem. 2016 Dec 23;291(52):26875-26885. doi: 10.1074/jbc.M116.746081. Epub 2016 Nov 14.

4.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.

Clin Cancer Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22.

5.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

6.

Genomically Incorporated 5-Fluorouracil that Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous Recombination.

Huehls AM, Huntoon CJ, Joshi PM, Baehr CA, Wagner JM, Wang X, Lee MY, Karnitz LM.

Mol Pharmacol. 2016 Jan;89(1):53-62. doi: 10.1124/mol.115.100164. Epub 2015 Oct 22.

7.

Molecular Pathways: Targeting ATR in Cancer Therapy.

Karnitz LM, Zou L.

Clin Cancer Res. 2015 Nov 1;21(21):4780-5. doi: 10.1158/1078-0432.CCR-15-0479. Epub 2015 Sep 11. Review.

8.

G2E3 attenuating replicative stress.

Schmidt F, Karnitz LM, Dobbelstein M.

Aging (Albany NY). 2015 Aug;7(8):527-8. No abstract available.

9.

UNC45A localizes to centrosomes and regulates cancer cell proliferation through ChK1 activation.

Jilani Y, Lu S, Lei H, Karnitz LM, Chadli A.

Cancer Lett. 2015 Feb 1;357(1):114-120. doi: 10.1016/j.canlet.2014.11.009. Epub 2014 Nov 10.

10.
11.

ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.

Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.

12.

Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.

Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH.

Clin Cancer Res. 2012 Oct 1;18(19):5364-73. doi: 10.1158/1078-0432.CCR-12-0961. Epub 2012 Aug 6.

13.
14.

Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.

Geng L, Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM.

PLoS One. 2011;6(12):e28862. doi: 10.1371/journal.pone.0028862. Epub 2011 Dec 15.

15.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P.

Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1.

16.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM.

Haematologica. 2011 Nov;96(11):1619-26. doi: 10.3324/haematol.2011.049551. Epub 2011 Jul 26.

17.

Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM.

Cancer Res. 2011 Jul 15;71(14):4944-54. doi: 10.1158/0008-5472.CAN-11-0814. Epub 2011 May 25.

18.

RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network.

Geng L, Huntoon CJ, Karnitz LM.

J Cell Biol. 2010 Oct 18;191(2):249-57. doi: 10.1083/jcb.201005101. Epub 2010 Oct 11.

19.

Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.

Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM.

Cancer Res. 2010 Nov 1;70(21):8642-50. doi: 10.1158/0008-5472.CAN-10-1345. Epub 2010 Sep 14.

20.

Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.

Wagner JM, Karnitz LM.

Mol Pharmacol. 2009 Jul;76(1):208-14. doi: 10.1124/mol.109.055178. Epub 2009 Apr 29.

21.

Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability.

Leonard JM, Ye H, Wetmore C, Karnitz LM.

J Cell Biol. 2008 Nov 3;183(3):385-91. doi: 10.1083/jcb.200804042. Epub 2008 Oct 27.

22.

Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

Gálvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM, Kaufmann SH.

Mol Pharmacol. 2008 Sep;74(3):724-35. doi: 10.1124/mol.108.047787. Epub 2008 May 28.

23.

Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I.

Hackbarth JS, Galvez-Peralta M, Dai NT, Loegering DA, Peterson KL, Meng XW, Karnitz LM, Kaufmann SH.

J Biol Chem. 2008 Jun 13;283(24):16711-22. doi: 10.1074/jbc.M802246200. Epub 2008 Apr 11.

24.

Functioning of the Hsp90 machine in chaperoning checkpoint kinase I (Chk1) and the progesterone receptor (PR).

Felts SJ, Karnitz LM, Toft DO.

Cell Stress Chaperones. 2007 Winter;12(4):353-63.

25.

The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1.

Delacroix S, Wagner JM, Kobayashi M, Yamamoto K, Karnitz LM.

Genes Dev. 2007 Jun 15;21(12):1472-7.

26.

Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em.

Karnitz LM, Felts SJ.

Sci STKE. 2007 May 8;2007(385):pe22. Review.

PMID:
17488976
27.

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.

Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, Robertson S, Murray L, Karnitz LM.

Cell Cycle. 2007 Jan 1;6(1):104-10. Epub 2007 Jan 7.

PMID:
17245119
28.

Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones.

Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, Karnitz LM.

J Biol Chem. 2006 Feb 3;281(5):2989-98. Epub 2005 Dec 5.

29.

Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.

Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, Lieberman HB, Chen J, Cliby WA, Kaufmann SH.

Mol Pharmacol. 2005 Dec;68(6):1636-44. Epub 2005 Aug 26.

30.

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM.

Blood. 2005 Jul 1;106(1):318-27. Epub 2005 Mar 22.

31.

The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.

Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, Kaufmann SH.

J Biol Chem. 2005 Apr 8;280(14):14349-55. Epub 2005 Feb 7.

32.

S-peptide epitope tagging for protein purification, expression monitoring, and localization in mammalian cells.

Hackbarth JS, Lee SH, Meng XW, Vroman BT, Kaufmann SH, Karnitz LM.

Biotechniques. 2004 Nov;37(5):835-9.

PMID:
15560139
33.

Rad9 protects cells from topoisomerase poison-induced cell death.

Loegering D, Arlander SJ, Hackbarth J, Vroman BT, Roos-Mattjus P, Hopkins KM, Lieberman HB, Karnitz LM, Kaufmann SH.

J Biol Chem. 2004 Apr 30;279(18):18641-7. Epub 2004 Feb 25.

34.

Purification and identification of protein complexes that control the cell cycle.

Burtelow MA, Podust VN, Karnitz LM.

Methods Mol Biol. 2004;241:247-53. No abstract available.

PMID:
14970659
35.

Identification and characterization of RAD9B, a paralog of the RAD9 checkpoint gene.

Dufault VM, Oestreich AJ, Vroman BT, Karnitz LM.

Genomics. 2003 Dec;82(6):644-51.

PMID:
14611806
36.

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.

Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM.

J Biol Chem. 2003 Dec 26;278(52):52572-7. Epub 2003 Oct 21.

37.

Cut5 is required for the binding of Atr and DNA polymerase alpha to genotoxin-damaged chromatin.

Parrilla-Castellar ER, Karnitz LM.

J Biol Chem. 2003 Nov 14;278(46):45507-11. Epub 2003 Oct 2.

38.
39.

Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling.

Roos-Mattjus P, Hopkins KM, Oestreich AJ, Vroman BT, Johnson KL, Naylor S, Lieberman HB, Karnitz LM.

J Biol Chem. 2003 Jul 4;278(27):24428-37. Epub 2003 Apr 21.

40.

Genotoxin-induced Rad9-Hus1-Rad1 (9-1-1) chromatin association is an early checkpoint signaling event.

Roos-Mattjus P, Vroman BT, Burtelow MA, Rauen M, Eapen AK, Karnitz LM.

J Biol Chem. 2002 Nov 15;277(46):43809-12. Epub 2002 Sep 11.

41.

Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9-1-1) DNA damage responsive checkpoint complex.

Burtelow MA, Roos-Mattjus PM, Rauen M, Babendure JR, Karnitz LM.

J Biol Chem. 2001 Jul 13;276(28):25903-9. Epub 2001 May 4.

42.

A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Sekulić A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT.

Cancer Res. 2000 Jul 1;60(13):3504-13.

43.

The human checkpoint protein hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9.

Rauen M, Burtelow MA, Dufault VM, Karnitz LM.

J Biol Chem. 2000 Sep 22;275(38):29767-71.

44.

Retention of the human Rad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage.

Burtelow MA, Kaufmann SH, Karnitz LM.

J Biol Chem. 2000 Aug 25;275(34):26343-8.

45.

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN.

Cancer Res. 2000 Apr 15;60(8):2108-12.

46.

The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade.

Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD, Gores GJ.

J Biol Chem. 2000 Jun 30;275(26):20210-6.

47.
48.

Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.

Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT.

Cancer Res. 1999 Sep 1;59(17):4375-82.

50.

A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf.

Sutor SL, Vroman BT, Armstrong EA, Abraham RT, Karnitz LM.

J Biol Chem. 1999 Mar 12;274(11):7002-10.

Supplemental Content

Loading ...
Support Center